Shigemasa et al (2003) reported that COX-2 expression might play an important role in ovarian carcinoma development. Ferrandina et al (2002) described that increased COX-2 expression was associated with chemotherapy resistance and outcome in ovarian carcinoma patients and then Denkert et al (2002) reported that COX-2 expression was an independent prognostic factor in ovarian carcinoma. More recently, COX-1 has been reported to contribute to carcinoma development in the ovary through stimulation of neovascularisation (Gupta et al, 2003). This evidence concerns the gene PTGS2 and carcinoma.